Implementation of medication review type 2a in community pharmacies: a longitudinal survey study
Eline Tobback, Isabelle De Wulf, Ella Wauters, Delia Mendez Santos, Stéphanie Patris, Olivia Dalleur, Eline Tommelein, Veerle Foulon, Geneviève Philippe, Carine De Vriese, Stephane Steurbaut, Nathalie Duquet, Guido R. Y. De Meyer, Hans De Loof

TL;DR
This study tracks how medication reviews are being implemented in Belgian pharmacies and identifies factors that help or hinder their success.
Contribution
The study provides longitudinal insights into MR2a implementation challenges and facilitators in community pharmacies.
Findings
Key barriers include time limitations, privacy-compliant communication systems, and personnel shortages.
Training and patient engagement are crucial facilitators for successful MR2a implementation.
Ongoing stakeholder support and improved interprofessional collaboration are essential for progress.
Abstract
Medication Review Type 2a (MR2a), introduced to enhance medication use and health outcomes, has been reimbursed in Belgian community pharmacies since April 2023; however, its implementation status remains unreported. This longitudinal survey study aimed to document MR2a implementation among community pharmacists by identifying both facilitating and hindering factors. A bilingual online survey was distributed quarterly from October 2023 to October 2024 to all Belgian community pharmacies. The 45-item questionnaire—featuring multiple-choice, Likert scale, and open-ended questions—captured pharmacists’ experiences about MR2a. Across all rounds (n = 708), consistent findings emerged regarding key barriers and facilitators to MR2a implementation. Major challenges included time limitations, privacy-compliant communication systems, personnel shortages, inadequate consultation spaces and…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Practices and Patient Outcomes · Antibiotic Use and Resistance · Health Policy Implementation Science
